Yes, information from other companies is available
Post# of 36537
(Total Views: 679)
Posted On: 09/03/2021 4:29:55 PM
Yes, information from other companies is available, which prompts my concern from a couple of perspectives.
First, GNBT can't be the only company/entity working on a vaccine that approaches the virus the same way that NuGen claims to. If that is so, then I suspect another company will reach that finish line before NuGen, especially in light of the demonstrated failures to achieve goals here.
Second, and actually of more concern, is what appears on GNBT's own website. The "offending" language reads: "The Ii-Key technology and our proprietary vaccine discovery platform enables us to rapidly respond to emerging infectious disease threats. Our 20-year history of creating new vaccines against potentially pandemic viruses (SARS-1, Avian Influenza, Swine Flu) has positioned us to be a leader in the fight against COVID-19 with an Ii-Key-SARS-CoV-2 vaccine."
Did GNBT in fact create and sell vaccines for SARS-1, the bird flu, and swine flu? According to Joe in the 05/06/2021 CC (page 24 of the transcript), GNBT never actually produced a vaccine for the swine flu. Also the admission that GNBT "started looking at" the avian flu (page 25), but no indication that anything ever came of that, either. Apparently, as of 2015, there were no peptide vaccines approved for use in the U.S. (according to Advances in Protein Chemistry and Structural Biology, 2015), so I really am at a loss to understand how GNBT could have made that claim. Maybe something was "created," but it never made it out into the [medical/pharmacological] marketplace. Is this the "smoke and mirrors" we have been worrying about recently?
First, GNBT can't be the only company/entity working on a vaccine that approaches the virus the same way that NuGen claims to. If that is so, then I suspect another company will reach that finish line before NuGen, especially in light of the demonstrated failures to achieve goals here.
Second, and actually of more concern, is what appears on GNBT's own website. The "offending" language reads: "The Ii-Key technology and our proprietary vaccine discovery platform enables us to rapidly respond to emerging infectious disease threats. Our 20-year history of creating new vaccines against potentially pandemic viruses (SARS-1, Avian Influenza, Swine Flu) has positioned us to be a leader in the fight against COVID-19 with an Ii-Key-SARS-CoV-2 vaccine."
Did GNBT in fact create and sell vaccines for SARS-1, the bird flu, and swine flu? According to Joe in the 05/06/2021 CC (page 24 of the transcript), GNBT never actually produced a vaccine for the swine flu. Also the admission that GNBT "started looking at" the avian flu (page 25), but no indication that anything ever came of that, either. Apparently, as of 2015, there were no peptide vaccines approved for use in the U.S. (according to Advances in Protein Chemistry and Structural Biology, 2015), so I really am at a loss to understand how GNBT could have made that claim. Maybe something was "created," but it never made it out into the [medical/pharmacological] marketplace. Is this the "smoke and mirrors" we have been worrying about recently?
(3)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼